These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 7690090)
1. Cardiovascular profile of MPC-1304, a novel dihydropyridine calcium antagonist: comparison with other calcium antagonists. Kanda A; Haruno A; Miyoshi K; Tanahashi Y; Miyake H; Ichihara K; Okumura K; Nagasaka M J Cardiovasc Pharmacol; 1993 Jul; 22(1):167-75. PubMed ID: 7690090 [TBL] [Abstract][Full Text] [Related]
2. Cardiovascular properties of LF 2.0254, a new potent vasoselective calcium channel blocker with a slow onset of action. Pruneau D; Roy F; Brown NL Fundam Clin Pharmacol; 1990; 4(2):223-43. PubMed ID: 2112508 [TBL] [Abstract][Full Text] [Related]
3. Antihypertensive effects of MPC-1304, a novel calcium antagonist, in experimental hypertensive rats and dogs. Kanda A; Haruno A; Miyake H; Nagasaka M J Cardiovasc Pharmacol; 1992; 20(5):723-30. PubMed ID: 1280733 [TBL] [Abstract][Full Text] [Related]
4. PY 108-068: a calcium antagonist with an unusual pattern of cardiovascular activity. Hof RP Gen Pharmacol; 1985; 16(1):1-6. PubMed ID: 2579873 [TBL] [Abstract][Full Text] [Related]
5. Cardiac inotropic vs. chronotropic selectivity of isradipine, nifedipine and clevidipine, a new ultrashort-acting dihydropyridine. Segawa D; Sjöquist PO; Nordlander M; Wang QD; Gonon A; Rydén L Eur J Pharmacol; 1999 Sep; 380(2-3):123-8. PubMed ID: 10513571 [TBL] [Abstract][Full Text] [Related]
6. Effects of the calcium antagonist PY 108-068 on myocardial tissues in vitro and on reflex tachycardia in vivo. Hof RP; Scholtysik G J Cardiovasc Pharmacol; 1983; 5(2):176-83. PubMed ID: 6188886 [TBL] [Abstract][Full Text] [Related]
7. Coronary vasodilator and cardiac effects of NKY-722, a novel hydrophilic 1,4-dihydropyridine derivative, in the blood-perfused dog heart. Imagawa J; Satoh K; Taira N Cardiovasc Drugs Ther; 1989 Mar; 3(1):81-90. PubMed ID: 2487526 [TBL] [Abstract][Full Text] [Related]
8. Cardiac versus vascular effects of a new dihydropyridine derivative, CV-4093. In vitro comparison with other calcium antagonists. Nakaya H; Hattori Y; Nakao Y; Kanno M Eur J Pharmacol; 1988 Jan; 146(1):35-43. PubMed ID: 3350058 [TBL] [Abstract][Full Text] [Related]
9. Cardiovascular profile of Ro 40-5967, a new nondihydropyridine calcium antagonist, delineated in isolated, blood-perfused dog hearts. Orito K; Satoh K; Taira N J Cardiovasc Pharmacol; 1993 Aug; 22(2):293-9. PubMed ID: 7692172 [TBL] [Abstract][Full Text] [Related]
10. Reconsideration of vascular selectivity of dihydropyridine calcium antagonists: comparison of cardiovascular profile of mepirodipine, a novel dihydropyridine consisting of a single stereoisomer with (+)-(S)-(S) conformation, with those of nifedipine and nicardipine. Motomura S; Hashimoto K Jpn J Pharmacol; 1990 Feb; 52(2):319-30. PubMed ID: 2313939 [TBL] [Abstract][Full Text] [Related]
11. Are the cardiovascular effects of gentamicin similar to those of calcium antagonists? Gotanda K; Yanagisawa T; Satoh K; Taira N Jpn J Pharmacol; 1988 Jul; 47(3):217-27. PubMed ID: 3221528 [TBL] [Abstract][Full Text] [Related]
12. Effects of nilvadipine on the cardiovascular system in experimental animals. Ohtsuka M; Koibuchi Y; Sakai S; Tsujioka K; Fujiwara T; Ozaki T; Maeda K; Motoyama I; Horiai H; Ono T Arzneimittelforschung; 1988 Nov; 38(11):1605-18. PubMed ID: 3214444 [TBL] [Abstract][Full Text] [Related]
13. MPC-1304, another type of dihydropyridine, possessing highly potent vasodilating action. Miyoshi K; Kanda A; Miyake H; Ichihara K; Kamei H; Nagasaka M Eur J Pharmacol; 1993 Jul; 238(2-3):139-48. PubMed ID: 7691619 [TBL] [Abstract][Full Text] [Related]
14. Differential cardiovascular effects of calcium channel blocking agents: potential mechanisms. Millard RW; Lathrop DA; Grupp G; Ashraf M; Grupp IL; Schwartz A Am J Cardiol; 1982 Feb; 49(3):499-506. PubMed ID: 6277175 [TBL] [Abstract][Full Text] [Related]
15. Cardiac and vascular effects of NZ-105, a novel dihydropyridine derivative, in vitro. Masuda Y; Iwama T; Yamashita T; Sakai T; Hibi M; Tanaka S; Shigenobu K; Kasuya Y Arch Int Pharmacodyn Ther; 1991; 314():57-73. PubMed ID: 1668604 [TBL] [Abstract][Full Text] [Related]
16. The dihydropyridines modulate neurotensin inotropic action paradoxically. Golba KS; Deja M; Imiołek P; Kotyla PJ; Biernat J; Woś S; Herman ZS J Physiol Pharmacol; 1995 Dec; 46(4):419-27. PubMed ID: 8770786 [TBL] [Abstract][Full Text] [Related]
17. A comparison of an A1 adenosine receptor agonist (CVT-510) with diltiazem for slowing of AV nodal conduction in guinea-pig. Snowdy S; Liang HX; Blackburn B; Lum R; Nelson M; Wang L; Pfister J; Sharma BP; Wolff A; Belardinelli L Br J Pharmacol; 1999 Jan; 126(1):137-46. PubMed ID: 10051130 [TBL] [Abstract][Full Text] [Related]
18. In vitro assessment for vascular selectivity of a new dihydropyridine derivative, NB-818. Hattori Y; Fukao M; Houzen H; Qi F; Yamada Y; Kanno M Eur J Pharmacol; 1996 Apr; 301(1-3):99-106. PubMed ID: 8773452 [TBL] [Abstract][Full Text] [Related]
19. Effect of DHP-218, a novel dihydropyridine phosphonate, on atrioventricular nodal conductivity compared with its vascular effect in dogs. Taira N; Takahashi K; Hosono M J Cardiovasc Pharmacol; 1987 Sep; 10(3):274-9. PubMed ID: 2444774 [TBL] [Abstract][Full Text] [Related]
20. In-vitro negative chronotropic and inotropic effects of a novel dihydropyridine derivative, CD-832, in the guinea-pig: comparison with calcium-channel antagonists. Noguchi K; Takahashi K; Higuchi S J Pharm Pharmacol; 1998 Mar; 50(3):329-34. PubMed ID: 9600727 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]